GRI Bio, Inc..
GRI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
GRI Bio, Inc., is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory diseases are treated. They are developing a pipeline of novel, oral therapies designed to target the innate immune system by inhibiting the activity of Neutrophil Extracellular Traps (...Show More
Better Health for All
10
GRI Bio is a clinical-stage biopharmaceutical company entirely focused on developing novel therapies for inflammatory diseases, with its lead candidate, GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF). Pre-clinical data indicates GRI-0621 has anti-inflammatory and anti-fibrotic effects, performing as well as or better than the approved drug nintedanib.
1
Interim Phase 2a clinical trial data for GRI-0621, evaluating 24 patients at 6 weeks, shows it to be safe and well-tolerated, with no adverse events related to hyperlipidemia.
2
The company has no revenue from commercialized products, thus no revenue from harmful products. Clinical trial details for GRI-0621 are publicly available on clinicaltrials.gov (NCT06331624), and the study is described as randomized, double-blind, multi-center, and placebo-controlled, suggesting adherence to ethical standards.
3
The company's Code of Business Conduct and Ethics emphasizes compliance with healthcare regulations.
4
Fair Money & Economic Opportunity
0
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The provided articles discuss its public offerings, stock performance, and R&D expenses. There is no evidence to suggest that the company offers lending, deposit, or other financial services to consumers.
1
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as the company's core business lies outside the financial services sector.
2
Fair Pay & Worker Respect
0
No evidence available to assess GRI Bio, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No information regarding GRI.US's fair trade and ethical sourcing practices, including details on fair-trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was found in the provided articles.
1
Honest & Fair Business
0
No specific, concrete data points were found in the provided articles to assess GRI.US against any of the 'Honest & Fair Business' KPIs.
1
pertains to the Global Reporting Initiative (GRI), not GRI.US.
2
explicitly states that data is not available for GRI.US.
3
outlines the Audit Committee Charter but does not contain quantitative or specific qualitative data relevant to the defined KPIs.
4
Kind to Animals
0
Preclinical data for drug candidates GRI-0621 and GRI-0803 demonstrated positive results in animal models for idiopathic pulmonary fibrosis (IPF) and systemic lupus erythematosus (SLE), respectively.
1
However, the provided articles do not contain specific quantitative data or policy details required to score any of the 'Kind to Animals' KPIs, such as the number of animals used, the company's animal testing policy, or investment in animal-free alternatives.
No War, No Weapons
0
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The provided articles contain no evidence of the company being involved in arms manufacturing, military contracts, or conflict facilitation. The company's public offering proceeds are designated for product candidate development, working capital, and general corporate purposes, with no mention of defense-related activities or investments in dual-use technologies.
1
Planet-Friendly Business
0
No specific, quantitative evidence regarding GRI Bio, Inc.'s environmental performance, targets, or initiatives was found in the provided articles. The articles discuss the Global Reporting Initiative (GRI) standards and frameworks for sustainability reporting, not the operational data or environmental impact of GRI Bio, Inc.
1
Respect for Cultures & Communities
0
Sustainability data for GRI.US is currently unavailable, as explicitly stated in the provided articles.
1
This complete absence of information prevents any assessment against the specified KPIs related to Respect for Cultures & Communities.
2
Safe & Smart Tech
0
No evidence available to assess GRI Bio, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess GRI Bio, Inc. on Zero Waste & Sustainable Products.